ZUO LI YAO YE(300181) 上海证券报·2025-04-25 01:18Core Viewpoint - The company has reported its annual results, highlighting its main business in pharmaceutical research, production, and sales, with a focus on traditional Chinese medicine and innovative drug development [1][2]. Company Overview - The company specializes in the research, production, and sales of pharmaceuticals, with key products including various traditional Chinese medicine formulations and innovative drugs targeting specific health conditions [2][3]. Main Products - Wuling Capsule: A unique product and a national class I new drug, primarily used in various medical fields for its cognitive enhancement and anxiety relief properties. It has been included in 80 clinical guidelines and expert consensus documents [2][3]. - Lingze Tablet: An innovative drug for benign prostatic hyperplasia, recognized for its unique mechanism of action and included in 12 clinical guidelines [3]. - Linglianhua Granules: A product aimed at alleviating menopausal symptoms, now classified as a non-prescription drug and recommended in clinical guidelines [4]. - Bailing Tablet and Capsule: Both products are used for respiratory and renal conditions, with significant clinical research supporting their efficacy in chronic obstructive pulmonary disease and chronic kidney disease [4][5]. - Psyllium Calcium Tablet: A first generic drug for irritable bowel syndrome, recommended in multiple clinical guidelines for its safety and efficacy in treating constipation [5]. Financial Data and Shareholder Information - The company has undergone a change in its accounting firm, now audited by Zhonghui Accounting Firm, and has proposed a cash dividend of 6.00 yuan per 10 shares [1]. - As of the report date, the company has a total of 14,895,074 shares held in its repurchase account, representing 2.12% of the total share capital [8]. Important Events - The company received a drug registration certificate for Bailing Capsule from the National Medical Products Administration [9]. - The company has adjusted the timeline for several fundraising investment projects, including the construction of an intelligent traditional Chinese medicine production base [10]. - A strategic cooperation framework agreement was signed with Lingyi (Hangzhou) Biotechnology Co., Ltd. to enhance collaboration in the pharmaceutical sector [14].